South African pharmaceutical manufacturer Adcock Ingram on February 24 reported a 4% increase in turnover, to R3.8-billion, for the six months ended December 31, 2020, during which the group experienced challenging trading conditions brought on by the Covid-19 pandemic, as well as a depressed economy and lower demand for certain categories of medicine and products. CEO Andy Hall, however, said that, despite these challenges, “Covid-19 has also presented the company with opportunities to adapt to the ever-changing environment, and at the same time, deliver on its promise of ‘adding value to life’ by producing and supplying life-saving and acute medicines especially at a time when they are needed most”.
from Engineering News | Home https://ift.tt/3pPXbkY
